Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation
Giulio Metro(University of Perugia), Lucio Crinò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Rita Chiari(Azienda Ospedaliera di Perugia), Lorenza Pistola(Azienda Ospedaliera di Perugia), Francesca Romana Tofanetti(Azienda Ospedaliera di Perugia), Chiara Bennati(Azienda Ospedaliera di Perugia), M. Ferraldeschi(Azienda Ospedaliera di Perugia), Matthias Fischer(Goethe University Frankfurt), Vienna Ludovini(University of Perugia), Diana Giannarelli(Agostino Gemelli University Polyclinic), Rita Bellavita(Azienda Ospedaliera di Perugia), Luca Marcomigni(Azienda Ospedaliera di Perugia), M. Mare(Istituto Oncologico Veneto), M. Meacci(Azienda Ospedaliera di Perugia), V. Minotti(Azienda Ospedaliera di Perugia), Dario Giuffrida
Cited by 19
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240
The Effects of Different Ventilatory Settings on Pulmonary and Systemic Inflammatory Responses During Major Surgery
|Anesthesia & Analgesia|2004|233